Clinical trialPhase 1Recruiting
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
A Clinical Study of CAR-NK Cells (CL-NK-003) in Patients With Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 12 February 2026
- Expected end
- December 2028
- Enrollment
- 9 participants
- Sites
- 1
- Primary outcomes
- Dose-limiting toxicity (DLT); Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE); Number of participants with abnormal clinical laboratory parameters reported as TEAE; Number of participants with abnormal vital signs reported as TEAE; Number of participants with change from baseline in QT/QTc interval in electrocardiogram
- Sponsor
- Other
- Results posted
- No
- Last update
- 23 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
A fixed-dose study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-003) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.